Drug Profile
Research programme: immune checkpoint protein inhibitors - Aurigene Oncology
Alternative Names: AUNP-12; AUR-012; NP-12 - Aurigene Oncology; PD-1 peptide antagonist - Aurigene Oncology; PDCD-1 protein inhibitors - Aurigene Oncology; TIGIT/ PD-L1 dual inhibitorsLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Peptides; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Bacterial infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 04 Jun 2021 Discontinued - Preclinical for Bacterial infections in India (Parenteral) (Aurigene Discovery Technologies, May 2021) (Pierre Fabre's pipeline, June 2021)
- 04 Jun 2021 Discontinued - Preclinical for Cancer in India (SC) (Aurigene Discovery Technologies, May 2021) (Pierre Fabre's pipeline, June 2021)